Institute of Hematology and Medical Oncology "Seràgnoli", University of Bologna, Italy.
Curr Oncol Rep. 2011 Oct;13(5):407-15. doi: 10.1007/s11912-011-0189-5.
Primary mediastinal diffuse large B-cell lymphoma is a quite rare clinicopathologic entity. Molecular analysis shows it to be distinct from other types of diffuse large B-cell lymphoma, and some retrospective analyses suggests that it may respond better to third-generation chemotherapy regimens than to the more commonly used CHOP. The addition of rituximab could reduce these differences; the role of consolidation with local radiotherapy, which is often used to treat residual mediastinal masses, remains. The real role of FDG-PET scanning requires prospective studies, and it is hoped that this may allow the de-escalation of radiation therapy accordingly to yield reliable prognostic information.
原发性纵隔弥漫性大 B 细胞淋巴瘤是一种相当罕见的临床病理实体。分子分析表明它与其他类型的弥漫性大 B 细胞淋巴瘤不同，一些回顾性分析表明，它可能对第三代化疗方案的反应优于更常用的 CHOP。利妥昔单抗的加入可以减少这些差异；局部放疗巩固的作用，这通常用于治疗残留的纵隔肿块，仍然存在。氟脱氧葡萄糖 - 正电子发射断层扫描的实际作用需要前瞻性研究，希望这可以相应地降低放疗的强度，从而提供可靠的预后信息。
